By Fineline Cube 
Germany-based pharmaceutical major Boehringer Ingelheim has entered into a multi-year strategic collaboration with Tempus (NASDAQ: TEM), leveraging Tempus’ AI-powered precision medicine platform to enhance the development of anti-tumor drugs. This partnership builds on previous joint efforts initiated in 2021 focused on digital biomarker discovery.
Collaboration Details
Tempus brings to the table its extensive database of molecular, clinical, and imaging data, along with its advanced analysis platform called Lens. Both parties will utilize patient data to guide biomarker development and patient stratification. They will also propose hypotheses for drug combination therapies, support the discovery of new targets, and gain deeper insights into patients’ diagnosis and treatment histories.-Fineline Info & Tech